<sup>177</sup> Lu-PSMA-617 Monotherapy Is Provocative but No Standard of Care for Metastatic Hormone-Sensitive Prostate Cancer
Giri et al. present a case report involving a patient with metachronous low-volume metastatic hormone-sensitive prostate cancer (mHSPC) who declined standard treatments such as androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPI), and taxane chemotherapy because of
Authors
- Silke Gillessen (ORCID: https://orcid.org/0000-0001-5746-6555)
- Boris Hadaschik
- Oliver Sartor
Institutions
- East Jefferson General Hospital (US)
- Ente Ospedaliero Cantonale (CH)
- Essen University Hospital (DE)
- Università della Svizzera italiana (CH)
Publication Details
- Journal
- Journal of Nuclear Medicine
- Published
- 2025-09-25
- DOI
- https://doi.org/10.2967/jnumed.125.270836
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00